BioAge Labs

Last week, BioAge visited Novartis to kick off our multi-year collaboration to discover novel targets for therapies that address age-related diseases! Our Aging and Physical Exercise Target Discovery (APEx) data science team met with Sophie Lemire-Brachat, Head of Translational and Data Science, Diseases of Aging and Regenerative medicine (DARe), and the Novartis DARe team in Boston to begin our joint work investigating the biological mechanisms that drive aging and mediate the beneficial effects of physical exercise. The collaboration will leverage BioAge's extensive proprietary human longevity datasets and Novartis expertise in exercise biology to identify and validate multiple novel drug targets, dramatically expanding our therapeutic reach and benefiting patients across multiple indications. Thanks to Sophie and the DARe team for a fantastic kickoff meeting — we're so excited to combine our unique capabilities to advance new approaches for diseases of aging. For more details about the agreement: https://lnkd.in/g3HNrNx5

Last week, BioAge visited Novartis to kick off our multi-year collaboration to discover novel targets for therapies that address age-related diseases! Our Aging and Physical Exercise Target Discovery (APEx) data science team met with Sophie Lemire-Brachat, Head of Translational and Data Science, Diseases of Aging and Regenerative medicine (DARe), and the Novartis DARe team in Boston to begin our joint work investigating the biological mechanisms that drive aging and mediate the beneficial effects of physical exercise. The collaboration will leverage BioAge's extensive proprietary human longevity datasets and Novartis expertise in exercise biology to identify and validate multiple novel drug targets, dramatically expanding our therapeutic reach and benefiting patients across multiple indications. Thanks to Sophie and the DARe team for a fantastic kickoff meeting — we're so excited to combine our unique capabilities to advance new approaches for diseases of aging. For more details about the agreement: https://lnkd.in/g3HNrNx5

"By redirecting resources into high-value partnerships and novel therapeutic strategies, BioAge is positioning itself to capitalize on its proprietary insights into aging biology in a way that could ultimately yield more effective interventions for metabolic diseases." Read Eleanor Garth's coverage of our most recent strategic updates in Longevity.Technology: https://lnkd.in/g3hf6TRZ

Today at the Toronto Aging Biology Symposium (TABS), BioAge COO and co-founder Eric Morgen, MD will join our friend Alex Colville, General Partner at age1, for a panel discussion on clinical trials in aging biology. They'll share perspectives on endpoints, participant selection, and regulatory considerations with an audience interested in translational aging research. Both panelists will also highlight their journeys into longevity biotech and the insights they’ve gained along the way. It’s a homecoming for Eric, who earned his MD at the University of Toronto! BioAge is a proud sponsor of TABS, which brings together internationally recognized leaders and scientists to cover topics on longevity research, clinical translation, startups and VC. More about the 2025 conference: https://lrc.bio/

Today BioAge is pleased to announce key updates on our programs and partnerships, including: • Advancement of novel, structurally distinct APJ agonists, following the discontinuation of azelaprag; • Nomination of our novel, brain-penetrant NLRP3 inhibitor BGE-102 as a development candidate, with initial Phase 1 clinical data anticipated by end of 2025; • Formation of strategic partnerships with Novartis (announced in December) and Lilly ExploR&D (announced today) that expand our discovery efforts, leveraging BioAge's unique insights into the biology of human aging. More details in our press release: https://lnkd.in/gFXepnds

BioAge is proud to sponsor the 2025 Toronto Aging Biology Symposium, which will bring together internationally recognized leaders and scientists to cover topics on longevity research, clinical translation, startups and venture capital. Registration for the event is open now! https://lnkd.in/gS46Y9cA

The BioAge podcast, Translating Aging, features the people & organizations advancing the science of human longevity and discovering drugs to extend healthspan. Our newest episode just dropped!

Excellent coverage by Kyle LaHucik in Endpoints News about BioAge's recently announced collaboration with Novartis. Under the agreement, we will work to discover novel therapeutic targets that address age-related diseases, combining BioAge's human longevity datasets with Novartis expertise in the biology of exercise. https://lnkd.in/eTiSk7pK

Fierce Biotech covers BioAge's multi-year collaboration with Novartis, aimed at discovering novel therapeutic targets by investigating the biological mechanisms that drive age-related disease and mediate the beneficial effects of physical exercise.

I’m pleased to share that Novartis has entered a collaboration with BioAge Labs aimed at discovering novel targets for potential therapies that address diseases related to aging, with a focus on biological mechanisms underlying the beneficial effects of physical activity. By bringing together BioAge’s human longevity data and platform, and Novartis expertise led by our Diseases of Aging and Regenerative Medicine (DARe) group, we aim to uncover molecular drivers of age-related diseases and identify targets to pursue with innovative treatments. We look forward to the groundbreaking discoveries and advancements this collaboration could bring.